key: cord-0851293-uw5kr6hl
authors: Bhatia, R.; Sledge, I.; Baral, S.
title: The Missing Science: Epidemiological data gaps for COVID-19 policy in the United States
date: 2021-02-15
journal: nan
DOI: 10.1101/2021.02.11.21251602
sha: 682716704cb05b65137f936ef6a8b3dbb9c993e3
doc_id: 851293
cord_uid: uw5kr6hl

We report on a scoping study of COVID-19 epidemiological data available for COVID-19 policy and management decisions for U.S. settings. We synthesize current US Centers for Disease and Control and Prevention (CDC) estimates for parameter of infectious transmission, infection severity, and disease burden, and summarize epidemiologic contributions to these parameters published by CDC-affiliated investigators through Oct 30, 2020. Authoritative estimates of most infectious transmission and infection severity parameters exist but rely primarily on data from studies conducted in non-U.S. populations. Estimates of secondary infection risks for household, workplace, school, or other community settings are lacking and estimates of the clinical fraction remain uncertain. The CDC reports multiple disease incidence and prevalence measures at national and state geographies, including some measures disaggregated by age group, race/ethnicity and sex; however, nationally uniform disease burden measures are not available at the sub-state level or for sub-populations defined by exposure setting, limiting opportunities for targeted interventions. CDC-affiliated investigators authored 133 quantitative studies on COVID-19 through Oct 30, 2020; however only 34 employed analytic methods. The remainder were descriptive. Of the 34 analytic studies, eleven reported on risk factors for infection, seven reported on risk factors for severe disease, three on symptomatic infections, three reported secondary infection risks, and four reported on indirect pandemic effects. Gaps remain in the epidemiological data required for an efficient and equitable public health policy response to COVID-19. The existence of these gaps one year after the onset of the COVID-19 pandemic underscores the need for standardizing data collection and research priorities and protocols in the context of a rapidly emerging infectious disease epidemics.

In any emerging infectious disease epidemic, efficient and defensible disease control interventions will require timely and complete epidemiological data. The scope and severity of the US COVID-19 epidemic and its enormous social costs makes the need for actionable epidemiologic data particularly acute. Yet, one year after the discovery of the SARS-CoV-2 virus, the US Centers for Disease Control (CDC) acknowledges that "information about the biological aspects of SARS-CoV-2 and epidemiological characteristics of COVID-19 remain limited…." [1] Insufficient data on transmission mechanisms, setting and activity specific risks, and population-specific disease burden may have reduced the effectiveness, efficiency, and equity of the public health response. [2] An established literature on emerging respiratory virus epidemics provides a framework for evaluating the adequacy of Covid-19 data required for policy and management decisions. Lessons learned from prior epidemics including H1N1 influenza (H1N1), Severe Adult Respiratory Syndrome (SARS-CoV-1), and Middle-East Respiratory Syndrome (MERS) all inform CDC pandemic plans for emerging influenza viruses. The CDC's pandemic interval framework [3] and the pandemic severity assessment framework [4] explicitly spell out the scientific and data needs for assessing the risks posed by emerging respiratory viral infections. Reviews critically examining the epidemiology of the H1N1 pandemic response elaborate on these data demands, [5, 6, 7, 8] which were re-iterated at the onset of the COVID-19 pandemic. [9, 10] A scoping study is a method to examine the extent, range, nature of evidence or research activities in a particular field and to identify research gaps. [11] Here, we report on a scoping study of COVID-19 epidemiologic parameters for infectious transmission, infection severity, and disease burden which, collectively, inform the threat level posed by an emerging respiratory virus epidemic and guide an efficient, proportional and equitable public health response. [8] . We first synthesize current authoritative federal government appraisals for each of these parameters. We then summarize the methods and outcomes of epidemiologic investigations published by CDC-affiliated investigators informing the aforementioned parameters. We focus specifically on CDC appraisals and investigations because of the 4 agency's unique access to the data required for COVID-19 epidemiology, its partnerships with state and local public health authorities, and its leadership role in pandemic management. We identify knowledge gaps and suggest opportunities to improve the evidence base for COVID-19 mitigation. Table 1 summarizes the parameters for infectious transmission, disease severity, and disease burden that we sought along with their typical data sources.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.11.21251602 doi: medRxiv preprint Transmission studies, which observe individuals with confirmed infection and the people they infect secondarily, provide data on the mechanism of transmission (e.g. person to person through respiratory secretions), the incubation period (how long after infection symptoms appear), the generation interval (the time between a person becoming infected and subsequently infecting someone else), the infectivity period (how long an infected person can spread the illness), and the risk of infection among exposed contacts in various settings (secondary infectious risks/secondary attack rates). Transmission studies also identify populations relatively more susceptible to infection as well as groups or settings relatively more likely to contribute to transmission. [12] Additionally, transmission studies can quantify presymptomatic transmission and the proportion of infections that are symptomatic (the clinical fraction). These latter two parameters will, in part, determine the feasibility of isolation and contact tracing strategies. [13, 14] Optimal understanding of transmission and an equitable mitigation response requires that studies include diverse community settings (e.g., household, workplace, school, and congregate living such as long-term care facilities and shelters). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.11.21251602 doi: medRxiv preprint Optimally, data on the incidence of infection-related illness should be available in real time and disaggregated by population subgroup, setting, severity and patient characteristics to inform timely, targeted community mitigations and anticipation of healthcare needs.

The CDC's Pandemic Severity Assessment Framework (PSAF), an element of the national pandemic strategy, integrates the aforementioned transmission, severity and disease burden parameters into a qualitative assessment of the threat posed by an emerging infection. [4] Such risk assessments should be updated as the epidemic evolves, and data improves. We accessed public CDC webpages (See list in supplemental Materials, Table S2 ) to find current federal estimates of SARS-CoV-2 transmission, infection severity, and disease burden parameters and their data sources. We also searched specifically for documents containing applications of pandemic risk assessment tools, such as the PSAF. . We included studies published from 1 Jan to 30 Oct 2020. We excluded studies that did not present quantitative data.

We classified each included study as either descriptive or analytic and then abstracted published information on study design, data source, setting, population, and outcomes. (Supplemental Materials, Table S3 ) We considered a study descriptive if it did not evaluate or formally test a hypothesis using a . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.11.21251602 doi: medRxiv preprint well-established epidemiological method. We classified studies that quantified risk of infection, disease severity, or transmission through an established epidemiological method as analytic. If a study reported both descriptive and analytic components, we classified it as analytic.

We subcategorized descriptive studies by their design as: case study, case series, cluster or outbreak investigation, cross-sectional or ecologic survey. We categorized the designs of analytic studies as either cross-sectional, case-control, ecologic prospective cohort, or retrospective cohort designs. We identified each study's data source as either passive, sentinel, syndromic, or active surveillance programs, administrative program records, medical records, or survey instruments. We also categorized each study with regards to its setting and population.

We abstracted study outcomes as reported by the investigators. For each study other than those in the case studies and the case series, cluster and outbreak categories investigations, we identified outcomes contributing to any of the key aforementioned epidemiologic parameters. Table 2 synthesizes CDC's current estimates of epidemiologic parameters for SARS-CoV-2 transmission, infection severity and disease along with the estimates referenced sources.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.11.21251602 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 12, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 12, 2021. With regards to disease severity, CDC estimates the asymptomatic fraction as 40% but with a wide range (10-70%) based on summary estimates from meta-analytic reviews as well as individual studies.

[1] CDC estimated case fatality and case hospitalization ratios in May 2020 but later removed these parameters.

[37] In September 2020, CDC adapted infection fatality ratios from an analysis of European data. [1] CDC estimates risk ratios for hospitalization and death for age groups and race/ethnicity based on data from the COVID-NET active surveillance program.

[38] No estimates of relative risks for infection, hospitalization or death exist for occupations or particular community activities or settings.

Since April 2020, CDC has reported several COVID-19 disease incidence measures on a weekly basis, including emergency department visits for coronavirus-like illness (CLI), SARS-CoV-2 associated hospital admissions, and deaths from pneumonia, influenza, and COVID-19 [39] . CDC additionally reports some of these incidence measures at the level of states or multi-state regions. CLI emergency department visits represent those for fever plus cough and/or shortness of breath or difficulty breathing and come from National Syndromic Surveillance Program (NSSP) that collects and integrates data on ED visit symptoms from a large share of the countries emergency department in 47 states. CDC's COVID-NET program conducts active surveillance for laboratory-confirmed SARS-CoV-2 hospitalizations in 13 participating sub-state regions publishing age-stratified incidence rates weekly. CDC reports the percentage of deaths attributed to pneumonia or influenza as well as weekly counts of COVID-19 attributed deaths for each . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.11.21251602 doi: medRxiv preprint state parsed by age, gender, and race / ethnicity. Total excess deaths by cause of death is also available for each state. [40] In July 2020, CDC reported seroprevalence estimates from 10 sites based on COVID-19 antibodies detected in serum samples collected by commercial laboratories for reasons other than COVID-19. [41] After Aug 2020, CDC expanded seroprevalence reporting to all U.S. states and has been reporting estimates every two weeks. In December 2020, CDC provided the first estimates of cumulative prevalence of infection and symptomatic infection at a national level. [42] CDC affiliated investigators published 133 epidemiologic studies through Oct 30, 2020. (Supplemental   materials Table S3 ) Of these 133 studies, 99 were descriptive and 34 analytic. Table 3 tabulates study characteristics for both groups of studies.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.11.21251602 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 12, 2021 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 12, 2021. 1 All studies classified except those with case study or case series design . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.11.21251602 doi: medRxiv preprint

Of the 99 descriptive studies we identified, thirty-one were case series, 43 were cross-sectional, and 25 were ecologic. Most descriptive studies summarized laboratory confirmed cases of SARS-CoV-2 infection from a particular setting, disaggregating counts by clinical outcomes, by patient demographic or medical attributes, by exposure type, or by temporal patterns. Descriptive studies reported data from a wide range of populations and community settings.

Some descriptive studies postulated mechanisms of transmission or prevention; however, they did not estimate quantitatively infection transmission or disease severity parameters. Sixteen of the descriptive studies reported on the incidence or prevalence of laboratory confirmed infection, clinical illness, hospitalization or death in either the general population or a defined subpopulation (e.g., skilled nursing facility residents, healthcare workers, incarcerated or homeless individuals) for a defined time period. [43, 44, 45, 46, 47, 41, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57] . One study provided a point estimate of excess deaths associated with COVID-19 using national vital statistics data. [57] We classified thirty-four studies as analytic. Most Most analytic studies estimated at least one parameter for transmission, infection severity, or disease burden. Of the analytic studies estimating transmission parameters, three estimated secondary infection risks (SIR) [58, 59, 60] One of these was a follow up study of the first 12 confirmed cases in the US [58] Two others estimated the SIR for household contacts [59, 60] . Our searches found no studies estimating the SIR for workplace, school or community settings or for particular occupations or industries.

Eleven analytic studies provided estimates of an effect measure for risk factors for laboratory-confirmed infections. [59,61, 62, 63, 64, 65, 66, 67, 68, 69 ,70] Five of the eleven were conducted using a sample of the general population. These examined the frequency or particular demographics, [61] neighborhood deprivation/social vulnerability levels, [63, 68] relationship to a confirmed case, [59] and recent social . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.11.21251602 doi: medRxiv preprint activities, including restaurant dining. [66] Other investigations examined various factors related to confirmed infection in sub-populations, including face coverings and distancing among occupants of a military ship, [62] ethnic composition of employees of industrial facilities, [64] shelter residence status among people experiencing homelessness, [69] screening strategies and staffing levels in skilled nursing facilities. [65, 67] Eight of the eleven studies employed cross-sectional or ecologic designs. No studies examined the independent effects of etiologic variables in multi-variate analysis.

Seven studies examined risk factors for severe disease outcomes, including hospitalization, ICU stay and death. Most of these used general population subjects. [52, 63,71, 72, 73, 74 ,75] These studies consistently found older age to be a strong predictor of need for ICU stays, mechanical ventilation and of death. Male gender, end-stage renal disease, coronary artery disease, and neurologic disorders, immunocompromising conditions, pregnancy, African American identity were also correlated with severe disease. [71, 72, 73, 52, 75] One study estimated the odds of prolonged symptoms in relation to disease severity. [74] No CDC-affiliated studies estimated infection-hospitalization or infection-fatality ratios. Three studies assessed symptom prevalence or the fraction of symptomatic people among individuals with positive tests. One study, conducted in a military setting, found that 18.5% (44/238) of those with positive tests were asymptomatic. [62] Two community studies found that nearly all household contacts of an index case had symptoms or developed them shortly after testing positive. [76, 77] Nine analytic studies reported on indirect health impacts of COVID-19, including impacts on emergency departments visits, trends in childhood vaccination, telehealth visits, workplace absenteeism, mental health symptoms, and characteristics associated with delay or avoidance of medical care. [78, 79, 80, 81, 82, 83, 84, 85, 86] One found declines in emergency care visits for heart attacks, strokes, and diabetes; [81] one found an increased prevalence of mental health symptoms; [85] one found increased absenteeism in non-healthcare essential workers; [82] and two documented an initial decline followed by a rebound in childhood vaccination rates. [78, 83] . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.11.21251602 doi: medRxiv preprint

Twelve months after the identification of the SARS-COV-2 virus, epidemiologic understanding of infectious transmission, disease severity, and disease burden has evolved and advanced. However, despite a substantial number of original epidemiological investigations, our review finds data gaps which may limit efficient interventions to prevent COVID-19 transmission.

We restricted this scoping study to epidemiological studies authored or co-authored by CDC investigators. Thus, our review may have also overlooked data found in pre-prints and other unpublished analyses. However, estimating transmission, infection severity and disease burden parameters generally require detailed individual case records or contact tracing data for which access is restricted to government agencies.

CDC's current estimates of SARS-CoV-2 transmission parameters, including the incubation period, serial interval, and timing and duration of infectiousness, come from studies conducted outside the U.S. yet are consistent across settings and time-periods and thus considered reliable. On the other hand, CDC estimates of the clinical fraction have a wide range, reflecting significant heterogeneity among study methods, settings and populations. [87, 88, 89, 90] Large or multi-regional case-ascertained studies or examination of contact tracing follow up data conducted in the US could provide more precise and agespecific estimates of this parameter as well as of the impact of asymptomatic spread in different settings.

Context-specific estimates of the SIR, including for schools, workplaces, and other community settings, remain unavailable. These parameters require large or setting-specific transmission studies. Available estimates of the SIR for household transmission also vary widely with few based on US settings. No identified transmission studies have quantitatively examined the efficacy of modifying exposure factors within households or workplaces.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.11.21251602 doi: medRxiv preprint Current guidance for COVID-19 community mitigations relies primarily on indirect evidence. For example, pre-symptomatic transmission, proximity, and an inability to mask are the facts used to justify restrictions on indoor dining in restaurants; [91] Such restrictions may well be protective; however, rigorous studies quantifying transmission risks for restaurant settings have not been undertaken.

Studies comparing estimates of the SIR across community settings and activities could identify high risk activities and prioritize risk reduction interventions. Large coordinated case-ascertained prospective studies in particular could be a valuable tool to determine risks from specific activities in household, community, business, transportation, and educational settings and assess the risk reduction associated is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.11.21251602 doi: medRxiv preprint timing of secondary infections within households, demonstrating that about 5% happen >3 days after onset of symptoms. [93] A meta-analysis of 47 studies on transmission rates in households, schools, workplaces, and social events, including fifteen in settings within the U.S., identified multiple population determinants of secondary infection risks, including higher risks for students relative to teachers and for boarding versus day schools. [94] Disease Severity CDC's estimates of the infection-fatality ratios (IFR) based on studies in six European countries may not be generalizable to the US. County to country differences in the prevalence of vulnerability factors, medical care, and ascertainment of infection affect this parameter. Community cohort studies could provide assessment of multiple infection severity parameters.

While the CDC has established older age as a strong risk factor for severe COVID-19 disease and characterized the relative risk associated with individual medical co-morbidities, [95] further inquiry could examine how the effects of age and co-morbidities vary for individuals with different levels of functional status and in different residential settings (e.g., skilled nursing, assisted living or independent community living).

To monitor disease burden, the CDC has routinely reported several measures of infection and disease incidence at the national and state level; however, these measures have limited geographical resolution.

Each state has utilized its own distinct sets of state and regional indicators, [96] along with state-specific benchmarks, to guide control activities.

For calibrating mitigations, most states have relied heavily on laboratory-test-based "case" counts, which underestimate infection rates and vary depending on testing access and demand. [97, 6] For such . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.11.21251602 doi: medRxiv preprint reasons, the US National Pandemic Strategy called for transitioning from counting individual confirmed cases to monitor epidemic trends to monitoring illness rates (i.e., hospitalization admissions and syndromic surveillance) which are generally less subject to bias. [3] In fact, during the H1N1 pandemic, CDC discontinued state reporting of individual lab-confirmed cases two months after the initiation of the epidemic and initiated state reporting of total numbers of weekly H1N1 hospitalizations and deaths. [5] The CDC used these numbers along other surveillance data to provide monthly estimates of symptomatic illness, hospitalizations, and deaths. [98] During H1N1, CDC also used syndromic surveillance data to model infection dynamics at sub-state regional level, illustrating important regional and temporal patterns of transmission relevant for control and planning decisions. [5] A robust, national approach to monitoring COVID-19 in every region using multiple measures of disease incidence should be feasible. In July 2020, the US Department of Health and Human Services required all hospitals to report COVID-19 associated admissions to the Federal government as part of a new national reporting standard; this data should allow publishing real time estimates of new hospital admissions by age at a regional level. Coronavirus-like-illness emergency department visits from the NSSP could also be a nationally consistent regional measure. Consistent application of surveillance measures across U.S. regions could lead to better informed and targeted mitigations and their evaluation.

Disaggregating measures of infection and disease burden by community setting (e.g. residential setting, workplaces, neighborhoods) could further aide in targeting public health responses and focusing resources for testing, contact tracing and outbreak investigations. Since May, CMS has required reporting of confirmed cases and deaths from regulated skilled nursing facilities; however, there is still little systematic data on the burden of infection, morbidity, and mortality in other community settings. Through the National Notifiable Disease Surveillance System (NNDSS), CDC has accumulated over 20 million case reports. These reports should contain exposure information on residence, occupation, travel.

Analytic studies could combine exposure prevalence among confirmed cases along with population exposure prevalence to estimate attributable risks for each exposure.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.11.21251602 doi: medRxiv preprint

The US currently lacks regional estimates of the cumulative infection prevalence. Regional differences in prevalence could explain part of the variation in the pace of infectious spread. Methods to assess exposure using antibodies have evolved and improved over the epidemic time course. [99, 100] Applying serial seroprevalence studies both to estimate cumulative incidence and infection fatality rates should be an important subject of investigation. These epidemiological data gaps may be limiting the most efficient and equitable response to the COVID-19 epidemic and underscore the importance of standardizing data collection priorities and protocols early during a rapidly emerging infectious disease epidemic. CDC scientists and staff have authored a large number of studies on COVID-19; however, the majority are descriptive and provide low-quality evidence for policy and management decisions. The content of their investigations raises questions about whether and how an explicit national research agenda guided CDC epidemiological endeavors.

CDC scientists have the access to data, the expertise, and the resources to provide the data necessary for an optimal epidemic response. Moving forward, the CDC should now plan for how it might develop and implement a timely, strategic, and prioritized national epidemiological data collection and research agenda for the next emerging infectious disease epidemic.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (7) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.11.21251602 doi: medRxiv preprint

Updated preparedness and response framework for influenza pandemics

Novel framework for assessing epidemiologic effects of influenza epidemics and pandemics

Epidemiology of 2009 pandemic influenza A (H1N1) in the United States

The effectiveness of U.S. public health surveillance systems for situational awareness during the 2009 H1N1 pandemic: a retrospective analysis

Managing and reducing uncertainty in an emerging influenza pandemic

8Improving the evidence base for decision making during a pandemic: the example of 2009 influenza A/H1N1

Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review

Defining the Epidemiology of Covid-19 -Studies Needed

Advancing scoping study methodology: a web-based survey and consultation of perceptions on terminology, definition and methodological steps

Household transmission of influenza virus

The interval between successive cases of an infectious disease

Factors that make an infectious disease outbreak controllable

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Incubation period of COVID-19: a rapid systematic review and meta-analysis of observational research

Centers for Disease Control and Prevention. National Center for Health Statistics Provisional COVID-19 Death Counts

Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States

Estimated incidence of COVID-19 illness and hospitalization -United States

Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 -COVID-NET, 14 States

COVID-19 Homelessness Team. Assessment of SARS-CoV-2 Infection Prevalence in Homeless Shelters -Four

New York City Department of Mental Health and Hygiene Covid-19 Response Team. Preliminary Estimate of Excess Mortality During the COVID-19 Outbreak

Evidence for Limited Early Spread of COVID-19 Within the United States

Detection and Genetic Characterization of Community-Based SARS-CoV-2 Infections

JE; CDC Field Surveyor Team. Estimated Community Seroprevalence of SARS-CoV-2 Antibodies -Two Georgia Counties

Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample -Indiana

Notes from the Field: Seroprevalence Estimates of SARS-CoV-2 Infection in Convenience Sample -Oregon

Facility-Wide Testing for SARS-CoV-2 in Nursing Homes -Seven

Garg S; COVID-NET Surveillance Team. Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 -COVID-NET, 14 States

Mass Testing for SARS-CoV-2 in 16 Prisons and Jails -Six Jurisdictions

Notes from the Field: Universal Statewide Laboratory Testing for SARS-CoV-2 in Nursing Homes -West Virginia

Seroprevalence of SARS-CoV-2 Among Frontline Health Care Personnel in a Multistate Hospital Network -13 Academic Medical Centers

SARS-CoV-2-Associated Deaths Among Persons Aged <21 Years -United States

Excess Deaths Associated with COVID-19, by Age and Race and Ethnicity -United States

Active Monitoring of Persons Exposed to Patients with Confirmed COVID-19 -United States

Household Transmission of SARS-CoV-2 in the United States

Transmission of SARS-COV-2 Infections in Households -Tennessee and Wisconsin

Response Team. COVID-19 Testing, Epidemic Features, Hospital Outcomes, and Household Prevalence

SARS-CoV-2 Infections and Serologic Responses from a Sample of U.S. Navy Service Members -USS Theodore Roosevelt

Disparities in COVID-19 Incidence, Hospitalizations, and Testing, by Area-Level Deprivation -Utah

Racial and Ethnic Disparities Among COVID-19 Cases in Workplace Outbreaks by Industry Sector -Utah

Association Between CMS Quality Ratings and COVID-19 Outbreaks in Nursing Homes -West Virginia

Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities -United States

Preventing COVID-19 Outbreaks in Long-Term Care Facilities Through Preemptive Testing of Residents and Staff Members -Fulton County

Association Between Social Vulnerability and a County's Risk for Becoming a COVID-19 Hotspot -United States

COVID-19 Prevalence among People Experiencing Homelessness and Homelessness Service Staff during Early Community Transmission

COVID-19 Outbreak Among a University's Men's and Women's Soccer Teams

CDC COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 -United States

Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status -United States

CDC COVID-19 Response Clinical Team. Characteristics Associated with Hospitalization Among Patients with COVID-19

Feldstein LR; IVY Network Investigators; CDC COVID-19 Response Team; IVY Network Investigators. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network -United States

Predictors at admission of mechanical ventilation and death in an observational cohort of adults hospitalized with COVID-19

A Prospective Cohort Study in Nonhospitalized Household Contacts With Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Symptom Profiles and Symptom Change Over Time

Loss of Taste and Smell as Distinguishing Symptoms of COVID-19

Effects of the COVID-19 Pandemic on Routine Pediatric Vaccine Ordering and Administration -United States

Decline in Child Vaccination Coverage During the COVID-19 Pandemic -Michigan Care Improvement Registry

National Syndromic Surveillance Program Community of Practice. Impact of the COVID-19 Pandemic on Emergency Department Visits -United States

Potential Indirect Effects of the COVID-19 Pandemic on Use of Emergency Departments for Acute Life-Threatening Conditions -United States

Increases in Health-Related Workplace Absenteeism Among Workers in Essential Critical Infrastructure Occupations During the COVID-19

Notes from the Field: Rebound in Routine Childhood Vaccine Administration Following Decline During the COVID-19 Pandemic

Delay or Avoidance of Medical Care Because of COVID-19-Related Concerns -United States

Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic -United States

Trends in the Use of Telehealth During the Emergence of the COVID-19 Pandemic -United States

Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review

Age-dependent effects in the transmission and control of COVID-19 epidemics

Probability of symptoms and critical disease after SARS-CoV-2 infection

Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis

Summary of Guidance for Public Health Strategies to Address High Levels of Community Transmission of SARS-CoV-2 and Related Deaths

Household transmission of 2009 pandemic influenza A (H1N1) virus in the United States

CIDE Coronavirus Simulation Model

The Household Secondary Attack Rate of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Rapid Review

Attack rates assessment of the 2009 pandemic H1N1 influenza A in children and their contacts: a systematic review and metaanalysis

Failing the Test -The Tragic Data Gap Undermining the U.S. Pandemic Response

How to maintain surveillance for novel influenza A H1N1 when there are too many cases to count

Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States

Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison

Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients